Drug development in Canada is a long and complex process, and the market is competitive. At the heart of drug development is intellectual property (IP). Life sciences companies who develop an IP strategy at the outset of a new project have a competitive advantage by creating value, generating revenue, and obtaining market intelligence. Without a strategy, companies risk losing IP assets, missing out on investment opportunities, and being exposed to competition.
On Wednesday, October 20, join a panel of industry insiders who will discuss the key IP opportunities and strategies related to drug development in Canada. The panel will touch on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis, international filing strategies and portfolio management, and of course, the unique industry challenges brought to light due to the COVID-19 pandemic.
This event is sponsored by:
- Brian Kingwell, Partner, Gowling WLG
- Isabelle Riedl, Senior Supervisor, Intellectual Property, Medicago
- Sonia Ziesche, Principal, Patent Agent, Gowling WLG